Development and validation of a nomogram to predict survival for advanced male breast cancer

Zhang, Li‐Ping; Lin, Hui; Wang, Ai‐Jing

doi:10.1111/and.14479

Cited by 3 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar research was published by Zhang et al. ( 23 ). However, as we mentioned above, applying only Cox regression analysis was inadequate and would overestimate the risk of cancer-specific death, because aside from the primary tumor, there were other factors that might threaten their life ( 24 ), and death due to other causes actually acted as a competing event to death caused by MBC.…”

Section: Discussionsupporting

confidence: 88%

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Huang

Heringa³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMale breast cancer (MBC) is rare, which has restricted prospective research among MBC patients. With effective treatments, the prognosis of MBC patients has improved and developing a second primary malignancy (SPM) has become a life-threatening event for MBC survivors. However, few studies have focused on the prognosis of MBC patients and looked into the SPM issue in MBC survivors.MethodWe reviewed MBC patients diagnosed between 1990 and 2016 from the latest Surveillance, Epidemiology, and End Results (SEER) Plus database. Competing risk models and nomograms were conducted for predicting the risk of cancer-specific death and SPM occurrence. C-indexes, calibration curves, ROC curves, and decision curve analysis (DCA) curves were applied for validation.ResultA total of 1,843 MBC patients with complete information were finally enrolled and 60 (3.26%) had developed an SPM. Prostate cancer (40%) was the most common SPM. The median OS of all the enrolled patients was 102.41 months, while the median latency from the initial MBC diagnosis to the subsequent diagnosis of SPM was 67.2 months. The patients who suffered from an SPM shared a longer OS than those patients with only one MBC (p = 0.027). The patients were randomly divided into the development cohort and the validation cohort (at a ratio of 7:3). The Fine and Gray competing risk model was used to identify the risk factors. Two nomograms were constructed and validated to predict the 5-year, 8-year, and 10-year survival probability of MBC patients, both of which had good performance in the C-index, ROC curves, calibration plots, and DCA curves, showing the ideal discrimination capability and predictive value clinically. Furthermore, we, for the first time, constructed a nomogram based on the competing risk model to predict the 5-year, 8-year, and 10-year probability of developing an SPM in MBC survivors, which also showed good discrimination, calibration, and clinical effectiveness.ConclusionWe, for the first time, included treatment information and clinical parameters to construct a nomogram to predict not only the survival probability of MBC patients but also the probability of developing an SPM in MBC survivors, which were helpful in individual risk estimation, patient follow-up, and counseling in MBC patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Huang

Heringa³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…And the proportion who received adjuvant therapy (radiotherapy, 40.8%; chemotherapy, 53.9%) was significantly higher than that of all MBC patients (radiotherapy, 28.5%; chemotherapy, 36.1%), indicating that most MBCBM patients prefer non-surgical treatment. However, after performing the multivariate COX regression analysis and presenting the final nomograms, we noticed that surgery substantially improved prognosis in MBCBM patients (HR<1, P<0.05), which was consistent with previous studies (19,27,28,30). Radical mastectomy is significantly better than breast-conserving surgery and partial mastectomy and is the best surgical option.…”

Section: Malignant Tumor Cells Interfere With Bone Microenvironment H...supporting

confidence: 89%

“…MBCBM patients, on the other hand, had larger tumors, higher grades, later T/N stages, higher risks of metastasis, higher possibilities of non-surgical treatment, and shorter OS and CSS. In MBC patients, age and tumor size have been widely reported as independent prognostic factors (19,27,28). MBCBM patients with tumors more significant than 50 mm accounted for 34% of the study (Figure 1).…”

Section: Malignant Tumor Cells Interfere With Bone Microenvironment H...mentioning

confidence: 99%

“…However, the TNM staging system excludes critical clinical factors, including age, histological subtype, and treatment information. It is unsuitable for quantifying the risk probability of BM in patients with MBC and the likelihood of survival in patients with MBCBM (18,19). The nomogram has been extensively applied in diagnosing and prognostic research of malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk stratification system and visualized dynamic nomogram constructed for predicting diagnosis and prognosis in rare male breast cancer patients with bone metastases

Gao

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundBone metastases (BM) from malignant tumors could disrupt the balance between osteoclasts and osteoblasts and affect bone homeostasis. Malignant breast cancer (BC) is rare in male patients, and co-occurrence of BM is even rarer. Given its low incidence, there is limited research evaluating risk and prognosis. Despite the widespread application of nomograms to predict uncommon malignancies, no studies have constructed predictive models focusing on the diagnosis and prognosis of male breast cancer with bone metastases (MBCBM).MethodsThis study selected all male breast cancer patients (MBC) between 2010 and 2019 in the Surveillance, Epidemiology, and End Results (SEER) database. We used simple and multivariate Logistic regression analyses to identify independent risk factors for BM in MBC patients. Then simple and multivariate Cox regression analyses were employed to determine the independent prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in MBCBM patients. We established and validated three new nomograms based on these independent factors.ResultA total of 4187 MBC patients were included, with 191 (4.56%) having bone metastases at the time of diagnosis. The independent risk factors of BM in MBC patients included age, tumor size, marital status, T stage, and N stage. In MBCBM patients, independent prognostic factors for OS and CSS were both age, T stage, ER status, PR status, and surgery. The concordance index (C-index), the area under the curve (AUC) of the receiver operating characteristic curve (ROC), the calibration curve, and the decision curve analysis (DCA) confirmed that these three nomograms could accurately predict the diagnosis and prognosis of MBCBM patients with excellent discrimination and clinical utility superior to the TNM staging system. We then established two prognostic-based risk stratification systems and three visualized dynamic nomograms that could be applied in clinical practice.ConclusionIn conclusion, this study aimed to establish and validate an accurate novel nomogram to objectively predict the diagnosis and prognosis of MBCBM patients. On this basis, prognostic-based risk stratification systems and visualized dynamic nomograms were constructed to facilitate doctors and patients to quantify individual BM risk probability and survival probability to assist in personalized risk assessment and clinical decision-making.

show abstract

“…Early diagnosis and treatment were di cult with current medical conditions; thus, exploring the early prognostic biomarkers was pivotal to improve OS. Also, the predictive model based on the biomarkers could effectively predict the OS possibility, and further guide the choice of treatment, and nally improve the living quality for BC patients [5,6].…”

Section: Introductionmentioning

confidence: 99%

OCRL is a novel prognostic biomarker and its association with immunoregulation in breast cancer

Chen

Zhu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: OCRL (Oculocerebrorenal syndrome of Lowe Protein) was originally well-known as the Lowe’s protein. However, the expression, significance and regulation mechanisms of OCRL in any cancers were not clear. Methods: The bioinformation of breast cancer (BC) patients was required from TCGA (The Cancer Genome Atlas), and the expression was validated via IHC (immuno-histochemical analysis), qPCR and western blot. The UALCAN database was used to explore the promoter methylation level of OCRL and its role in gene silencing and survival. The prognostic roles of various clinicopathologic characteristics, including the OCRL, were evaluated by univariate and multivariate regression analysis. OCRL-related differentially expressed genes (DEGs) and their functions were explored by LinkedOmics database. The protein-protein interaction (PPI) and immunomodulatory roles were further analyzed with STRING and TISIDB database. Results: Compared with normal and paracancerous samples, the up-regulated expression of OCRL was identified in BC samples. The OCRL was co-expressed with a variety of unfavorable survival-related genes, which also was identified as an independent prognostic factor. Thus, the prognosis of BC patients with overexpressed OCRL was notably more unfavorable from TCGA database. Also, the hypomethylation of OCRL at certain sites was associated with gene silencing and poor survival. Moreover, the overexpression level of OCRL was negatively associated with the infiltration of the most immune cells and the expression of various immune biomarkers in BC. Finally, a OCRL expression-based nomogram integrating independent prognostic factors was constructed to predict at one-, five-, and ten-year the overall survival (OS). Conclusion: OCRL was a promising prognostic predictor and potential immune inhibition modulator.

show abstract

Development and validation of a nomogram to predict survival for advanced male breast cancer

Cited by 3 publications

References 53 publications

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients: a population-based analysis

Risk stratification system and visualized dynamic nomogram constructed for predicting diagnosis and prognosis in rare male breast cancer patients with bone metastases

OCRL is a novel prognostic biomarker and its association with immunoregulation in breast cancer

Contact Info

Product

Resources

About